Literature DB >> 26316912

Third-line treatment in metastatic renal cell carcinoma and bone metastases.

Daniel Y C Heng1.   

Abstract

Entities:  

Year:  2015        PMID： 26316912      PMCID： PMC4537339          DOI： 10.5489/cuaj.3238

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  2 in total

1.  Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Authors:  Roberto Iacovelli; Daniele Santini; Mimma Rizzo; Alessandra Felici; Matteo Santoni; Elena Verzoni; Cristina Masini; Francesco Massari; Nicola Calvani; Alessandra Mosca; Giuseppe Procopio
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

Authors:  Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.